(2S)-2-[[5-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]imidazole-4-carbonyl]amino]butanedioic acid
(2S)-2-[[5-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]imidazole-4-carbonyl]amino]butanedioic acid
(2S)-2-[[5-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]imidazole-4-carbonyl]amino]butanedioic acid 性质
熔点 | >189°C (dec.) |
---|---|
密度 | 2.18±0.1 g/cm3(Predicted) |
储存条件 | Hygroscopic, -20°C Freezer, Under inert atmosphere |
溶解度 | 甲醇(微溶)、水(微溶) |
形态 | 固体 |
酸度系数(pKa) | 1.86±0.10(Predicted) |
颜色 | 白色至类白色 |
稳定性 | 吸湿性 |
(2S)-2-[[5-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]imidazole-4-carbonyl]amino]butanedioic acid 用途与合成方法
N-琥珀酰基-5-氨基咪唑-4-羧酰胺5'-磷酸核糖是嘌呤代谢产物。 由于腺苷是神经元功能的有效抑制剂,可抑制几种兴奋递质的释放并引发神经元的直接过级化,因此腺苷琥珀酸裂合酶(ASase)缺乏症患者出现的症状可能反映了琥珀酰嘌呤对神经传递的干扰。
SAICAR 是嘌呤核苷酸从头合成的中间体,以同工酶选择性性方式激活 PKM2,EC50 为 0.3 mM。SAICAR 刺激 PKM2 并促进癌细胞在葡萄糖限制条件下的存活。
Human Endogenous Metabolite
|
SAICAR accumulation induces nuclear localization of PKM2. PKM2-SAICAR phosphorylates and activates Erk1/2, which in turn sensitizes PKM2 for SAICAR binding through phosphorylation. Additionally, PKM2-SAICAR was necessary to induce sustained Erk1/2 activation and mitogen-induced cell proliferation. SAICAR-PKM2 interaction is necessary and sufficient to induce H3 T11 and Erk1/2 phosphorylation.
Upon glucose starvation, cellular SAICAR concentration increases in an oscillatory manner and stimulates PKM2 activity in cancer cells. The SAICAR-PKM2 interaction also promotes cancer cell survival in glucose-limited conditions. In glucose-limited conditions, cells with higher SAICAR concentrations (
adsl-kd
cells or cells overexpressing PAICS) survive better while
paics-kd
cells died earlier than control-kd cells. SAICAR promotes cancer cell survival in glucose-limited conditions.
(2S)-2-[[5-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]imidazole-4-carbonyl]amino]butanedioic acid 价格(试剂级)
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024-11-08 | HY-126585 | (2S)-2-[[5-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]imidazole-4-carbonyl]amino]butanedioic acid | 3031-95-6 | 500μg | 2000 |
2024-11-08 | HY-126585 | (2S)-2-[[5-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]imidazole-4-carbonyl]amino]butanedioic acid | 3031-95-6 | 1mg | 3400 |